Pfizer has established the Pfizer Breakthrough Growth Initiative, through which Pfizer will invest up to $500 million in biotechnology companies to help provide funding and access to Pfizer’s scientific expertise to ensure continuity of biotechnology companies’ clinical development programs.

The Pfizer Breakthrough Growth Initiative will focus on making non-controlling equity investments in clinical-stage public companies, with a primary focus on companies with small- to medium-sized market capitalizations across a range of therapeutic categories that are consistent with Pfizer’s core areas of focus: internal medicine, inflammation & immunology, oncology, rare disease, vaccines and hospital products.  

Under the program, companies may also have the opportunity to access Pfizer’s expertise and resources in research, clinical development and manufacturing.

Source: Pfizer